Obesity Player Raising More Capital (ETRM)
EnteroMedics Inc. (NASDAQ: ETRM) is raising more capital than had been previously disclosed and its shares are getting hit as a result. The company which focuses on devices using neuroblocking...
View ArticleVIVUS Takes QNEXA Obesity Fight to Europe (VVUS)
VIVUS Inc. (NASDAQ: VVUS) has done what was expected. It is not going to bet its entire future on the US FDA regulatory process for its QNEXA obesity pill. The company is applying for marketing...
View ArticleWhat To Expect After MannKind’s Implosion (MNKD)
MannKind Corporation (NASDAQ: MNKD) is currently not looking kind nor like a very nice man(n). Shares of the already-controversial MannKind are getting crushed after the FDA sent the company a...
View ArticleClik here to view.
M&A Bonanza For Drug & Biotech in 2011 (MRK, PFE, ALXN, DNDN, HGSI, CEPH,...
The game of predicting mergers and acquisitions in the biotech and in pharma sectors is not a new one. The talk heats up, then it dies down. A deal comes, followed by another deal, and the activity...
View ArticleAfter Orexigen’s Implosion, Now What? (OREX, VVUS, ARNA, ABT)
Orexigen Therapeutics, Inc. (NASDAQ: OREX) is beyond ugly after the FDA said that the company must now submit more trial data before its new diet pill Contrave may be cleared for sale. The vote was...
View ArticleAlkermes & Elan, Game-Changing Deal For Both Companies (ALKS, ELN, JNJ, ACOR,...
The biotech sector has been full of consolidation and mergers of late, but now we have a new model whereby a smaller company is set to grow by taking a part of a larger company. We cannot exactly call...
View ArticleAnalysis Sizing Up FDA Approval Chances of Obesity Drugs (VVUS, OREX, ARNA)
We have a new report sizing up obesity drugs this morning from Bank of America Merrill Lynch. The long and short of the three ratings is that Orexigen Therapeutics, Inc. (NASDAQ: OREX) and Vivus, Inc....
View ArticleRare Analyst Calls With Huge Upside in Vical and VIVUS (VICL, VVUS, BMY)
Vical Inc. (NASDAQ: VICL) and VIVUS, Inc. (NASDAQ: VVUS) are both running higher this Friday on news that Credit Suisse initiated both biotech outfits with “Outperform” ratings. What matters more than...
View ArticleAlimera Implosion Analysis, What Is Next (ALIM, PSDV)
Alimera Sciences, Inc. (NASDAQ: ALIM) is the latest of the drug implosions and this one looks even worse than just severely damaging. The FDA’s complete response letter is really a request for...
View ArticleShouldn’t VIVUS Raise Capital Now? (VVUS)
While we have started mostly using The Wire at 247wallst.com for our biotech and active trader posts (among many other aspects 50 to 100 times per day), we have a question for BioHealthInvestor readers...
View Article
